Celularity Inc. Class A CELU 深 滬
已收盤 02-06 16:00:00 美东时间
1.30
+0.130
+11.11%
華盛通- 最 高1.31
- 今 開1.21
- 成交量 1.65万股
- 最 低 1.21
- 昨 收 1.17
- 總市值 3748.91万
- 52周最高 4.35
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 1.0007
- 委 比 73.60%
- 總股本 2883.78万
- 歷史最高 134.00
- 量 比 0.39
- 振 幅 8.55%
- 歷史最低 1.0007
- 每 手 1
- 風險率 0.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Celularity Files Prospectus For The Offering Of Up To 14.1M Shares Of Class A Common Stock
Celularity Inc. Up to 14,078,938 shares of Class A Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the "Selling Stockholders") are offering on a resale basis an aggregate
01-01 05:19
FDA Issues Warning Letter To Celularity Over Interfyl Marketing Claims; Co Says No Impact On Manufacturing Or Shipments
On December 1, 2025, Celularity Inc., (the "Company") received a warning letter (the "Letter") from the U.S. Food and Drug Administration (the "FDA"). The Letter relates to the use of certain marketing material for
2025-12-06 05:36
Celularity Files For 6M Series A Convertible Preferred Stock, Raising Up To $6.67M In Private Placement With Warrants
Private Placement Transaction On October 24, 2025, Celularity Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with an institutional investor (the "Investor"), pursuant to
2025-10-28 21:40
Celularity Announces Publication Of Its Phase 2 Study On PDA-002 Demonstrating Safety And Efficacy In Treating Complex Diabetic Wounds
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the publication of its Phase 2 study titled "Human
2025-10-14 20:49
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
Celularity Inc. announced positive results from its Phase 2 study of PDA-002, a placenta-derived stem cell therapy, for treating diabetic foot ulcers (DFU) complicated by peripheral artery disease (PAD). The study, published in the International Wound Journal, demonstrated that PDA-002 achieved durable wound healing with just two intramuscular doses. The therapy showed higher wound closure rates compared to placebo, particularly in patients with ...
2025-10-14 12:45
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
2025-09-10 18:01
WBB Securities Upgrades Celularity to Buy, Maintains Price Target to $6
WBB Securities analyst Steve Brozak upgrades Celularity (NASDAQ:CELU) from Hold to Buy and maintains the price target from $6 to $6.
2025-09-09 23:15
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance
Celularity Inc. filed its Q2 and Q1 2025 Form 10-Q quarterly reports on August 29, 2025, aligning with its updated Nasdaq compliance plan. The company regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing. CEO Robert J. Hariri highlighted the retirement of $32 million in senior secured debt and $9.6 million in interest, as well as internal restructuring and agreements with Celeniv Pte. Ltd. Celularity faces challenges, incl...
2025-09-03 12:00
美股大行评级 | 财报前夕，家得宝、劳氏、沃尔玛分别获大行上调目标价！瑞银下调赛富时目标价至260美元
今日重点评级关注：Craig-Hallum：维持Applied Digital"买入"评级，目标价从12美元升至23美元；HC Wainwright & Co.：维持Bitdeer Technologies"买入"评级，目标价从18美元升至19美元
2025-08-19 09:56
Celularity Sells IP to Celeniv, Reduces Debt
Celularity ( ($CELU) ) has shared an announcement. On August 13, 2025, Celulari...
2025-08-19 05:01
